SCHEDULE 13G/A: Sphera Funds Management Discloses 7.49% Stake in Outlook Therapeutics

Sphera Funds Management Ltd. and its affiliated entities have disclosed a 7.49% beneficial ownership stake in Outlook Therapeutics, Inc., comprising common stock and exercisable warrants.

Summary

• Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP collectively reported beneficial ownership of 2,571,426 shares of Outlook Therapeutics, Inc. Common Stock.
• This aggregate ownership represents 7.49% of the total outstanding Common Stock of Outlook Therapeutics, Inc.
• The percentage is calculated based on 32,620,177 shares of Common Stock outstanding as of March 13, 2025, as reported by the Issuer in its Rule 424(b)(3) prospectus filed on March 28, 2025.
• The beneficial ownership includes 1,714,284 warrants, each exercisable into one share of Common Stock.
• Specifically, Sphera Global Healthcare Master Fund holds 128,571 shares and 257,142 warrants, representing 1.12% of the total shares outstanding.
• Sphera Biotech Master Fund, L.P. holds 728,571 shares and 1,457,142 warrants, representing 6.37% of the total Common Shares outstanding.
• The reporting persons are organized under the laws of the State of Israel.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Outlook Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the issuer's performance or outlook. The sentiment is neutral.

Positives

• The disclosure of a significant stake by institutional investors like Sphera Funds Management can signal confidence in Outlook Therapeutics' long-term prospects.
• The investment includes a substantial number of warrants, indicating a potential future increase in Sphera's direct equity holding upon exercise.

Future Outlook

The document does not provide forward-looking statements or guidance from Outlook Therapeutics, Inc. It primarily details the beneficial ownership stake of Sphera Funds Management and its affiliates.

Management Comments

• Adi Hanetz, General Counsel for Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd., and Sphera Global Healthcare Management LP, certified that 'to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This filing is typical for institutional investors acquiring a significant stake (5% or more) in publicly traded companies, particularly in sectors like biotechnology where investment funds often take positions based on clinical trial progress or market potential. The disclosure provides transparency regarding major shareholders, which is crucial for market participants.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and trading activity.
• Potential Investors: Offers insight into the ownership structure and the involvement of major funds, which may inform investment decisions.

Key Dates

Keywords

Outlook Therapeutics, Sphera Funds Management, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investment, Biotechnology, Healthcare